Interdisciplinary Prostate Cancer Congress and Other Genitourinary Malignancies

Robert Dreicer, MD, MS, MACP, FASCO, discusses the limitations of using prostate-specific antigen levels alone to guide prostate cancer treatment.

Scott T. Tagawa, MD, MS, FACP, FASCO, highlights a key difference between oral androgen receptor inhibitor drugs and therapeutic radionuclides for the treatment of prostate cancer.

Scott T. Tagawa, MD, MS, FACP, FASCO, discusses that patients with advanced prostate cancer benefit from a multidisciplinary care team.

Following the important information provided by the phase 3 VESPER trial, Jean Hoffman-Censits, Md said there are several noteworthy ongoing phase 3 neoadjuvant immunotherapy studies in bladder cancer.

According to Primo Nery Lara, Jr, MD, frontline treatment options for metastatic renal cell carcinoma have been improving rapidly.

In recent years, the field of metastatic urothelial cancer has seen many new immunotherapy agents and targeted therapies that have improved patient outcomes.